During an interview with Nephrology Times to discuss his Kidney Week abstracts, Jonathan Barratt, PhD, called IgA nephropathy (IgAN) “the world’s most important kidney disease.” Although the comment was tongue-in-cheek, he has a point, judging by the attention IgAN received at this year’s event. Just consider the standing-room-only attendance on October 25 of the exhibitor spotlight Navigating IgA Nephropathy: Pathogenesis, the Role of APRIL, and Patient Case Study, sponsored by Otsuka. The discussion was led by Kenar D. Jhaveri, MD, and Heather Reich, MD, PhD, with the stated objectives of promoting (1) recognition of the disease burden ...
Nephrology Times
Nephrology Times delivers the latest news in kidney-related treatments and technologies with the goal of better informing care decisions and improving patient outcomes.
Advertisement
Sponsored Content
Qasim Butt, MD, describes the importance of hyperkalemia management and how LOKELMA can help.
Advertisement
Latest News
IgAN was a hot topic at ASN Kidney Week and was the focus of an exhibitor spotlight on pathogenesis and the role of APRIL.
Researchers identified risk factors for nonconcordance with CKD screening and treatment guidelines in patients with diabetes.
A study examined whether restarting RASi after discontinuation would improve kidney outcomes.
Researchers sought to determine whether a higher salt intake was associated with chronic kidney disease (CKD).
Could the systemic inflammatory response index (SIRI) be a useful measure of renal prognosis in IgA nephropathy (IgAN)?
Diffuse magnetic imaging resonance shows promise for evaluating clinical and pathological changes in patients with IgAN.
Patients who experienced an acute kidney injury had a greater risk of being diagnosed with dementia after the AKI incident.
Little research has focused on risk factors for and clinical outcomes of AKI in patients with SFTS.
Researchers estimated hyperkalemia incidence in patients with chronic kidney disease from routine clinical care.
Surveyed physicians indicated that IgAN patients were referred to them late and not all potential cases had a timely biopsy.
Expert Interviews
In Print
Tribute to Nicoloas Madias, amino acid infusion to reduce AKI risk, felzartamab results, and more.
American Transplant Congress, 61st ERA Congress, AKI risk prediction, effects of a lifestyle intervention, and more.
Conferences
The American Society of Nephrology's annual meeting to highlight the latest scientific and medical advances in the field
ATC provides a forum for exchange of new scientific and clinical information relevant to transplantation.
The annual nephrology meeting organized by the European Renal Association
The National Kidney Foundation's premier educational event designed for the interprofessional kidney health team
Podcasts
Listen to the second part of the discussion of Chapter 15 of Dr. Burton Rose's book, focused on diuretics.
It's time for another NephJC draft! This time the 2024 KDIGO CKD guideline draft is on the clock!
Results of Nefecon (budesonide) for IgA nephropathy set the stage for a glomerulonephritis renaissance.
Vlado Perkovic presented results from the FLOW trial at the 61st ERA Congress, making headlines worldwide.
Expert Columns
Critical Financial Shifts Ahead: How CY 2025 ESRD PPS Changes Could Impact Small Dialysis Facilities
Sarah Tolson reviews the key financial implications of the CMS proposed rule for the ESRD Prospective Payment System.
Ajay Singh pays tribute to the late nephrologist and researcher Nicolaos Madias, MD, of Tufts Medical Center.
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW.
It is essential for nephrology practices and dialysis centers to have backup methods for processing claims.
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
Knowledge Hubs
Advertisement
Advertisement
Nephrology Times Chair
Ajay K. Singh, MBBS, FRCP, MBASenior Nephrologist, Brigham and Women’s Hospital | Senior Associate Dean, Harvard Medical School
Editorial Board
Mohamed G. Atta, MD, MPHProfessor of Medicine, Johns Hopkins School of Medicine
Timothy E. Bunchman, MDProfessor and Director, Pediatric Nephrology, Transplantation, and Rheumatology, Children’s Hospital of Richmond at VCU
Suphamai Bunnapradist, MD, MSProfessor of Medicine, David Geffen School of Medicine at UCLA | Research Director, Kidney Transplant Program, UCLA
Fernando C. Fervenza, MD, PhDProfessor of Medicine, Division of Nephrology and Hypertension, Mayo Clinic
Kenneth A. Liss, DOPartner, Hypertension and Nephrology Association, Eatontown, NJ
Joel M. Topf, MD, FACPAssistant Clinical Professor of Medicine, Oakland University William Beaumont School of Medicine
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.